Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels

Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels

Abstract is missing (Short communication)

Bibliographic Details
Main Authors:	Christopher Willy Schwarz, Nikolai Dyrberg Loft, Claus Zachariae, Lone Skov
Format:	Article
Language:	English
Published:	Society for Publication of Acta Dermato-Venereologica 2020-09-01
Series:	Acta Dermato-Venereologica
Subjects:	psoriasis secukinumab ustekinumab diabetes mellitus hyperglycemia
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3620

Similar Items

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis
by: Misbah N. Ghazanfar, et al.
Published: (2019-07-01)

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
by: Luis E. Sánchez-Dueñas, MD, et al.
Published: (2020-07-01)

Interleukin 17 deficiency and implications in cutaneous and systemic diseases
by: Elizabeth Z. Welch, et al.
Published: (2015-07-01)

Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
by: Farzan Solimani, et al.
Published: (2019-07-01)

Furin Expression in Patients With Psoriasis—A Patient Cohort Endangered to SARS-COV2?
by: Thomas Graier, et al.
Published: (2021-02-01)

New approved drugs for psoriatic arthritis
by: F.M. Perrotta, et al.
Published: (2016-09-01)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
by: Emanuela Zagni, et al.
Published: (2021-09-01)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
by: Martina Burlando, MD, et al.
Published: (2020-05-01)

Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab)
by: Chau Yee Ng, et al.
Published: (2020-01-01)

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
by: Kiran Godse
Published: (2017-01-01)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019-01-01)

Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic
by: Abhishek De, et al.
Published: (2019-01-01)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01)

Biologicals in the treatment of psoriasis: The Indian perspective
by: Ajit B Janagond, et al.
Published: (2017-01-01)

Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study
by: Florian Anzengruber, et al.
Published: (2019-06-01)

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
by: D'Angelo S, et al.
Published: (2017-03-01)

Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
by: Mary Catherine G. Pangilinan, et al.
Published: (2020-08-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
by: Tanja Todberg, et al.
Published: (2020-08-01)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019-04-01)

Secukinumab: supervivencia en práctica clínica real
by: R. Ruiz-Villaverde, et al.
Published: (2021-04-01)

Therapeutic options and modern approaches for the treatment of Behcet’s disease
by: I.Yu. Golovach, et al.
Published: (2020-02-01)

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
by: Bruna Lavinas Sayed Picciani, et al.
Published: (2021-06-01)

RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01)

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01)

ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients
by: Peter E. H. Schwarz, et al.
Published: (2019-07-01)

Ankilozan Spondilit, Crohn Hastalığı ve Anti-tümör Nekroz Faktör-alfa Tedavi ile İndüklenen Psoriasis olan Hastada Ustekinumab Tedavisine Dramatik Yanıt
by: Sevilay Kılıç, et al.
Published: (2020-12-01)

Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature
by: Nawaf Almutairi, et al.
Published: (2020-01-01)

Successful Treatment of Paradoxical Psoriasis with IL 17 Inhibition: Case Reports
by: Gamze Gül Güleç, et al.
Published: (2020-02-01)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019-09-01)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
by: Rossana Tiberio, et al.
Published: (2019-09-01)

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
by: Juul M.P.A. van den Reek, et al.
Published: (2018-04-01)

Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi’s Varicelliform Eruption
by: Anna Campanati, et al.
Published: (2019-09-01)

Real-life efficacy and safety of secukinumab: A single-center, retrospective observational study with 52-week follow-up
by: Shekhar Neema, et al.
Published: (2019-01-01)

Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial
by: Andreas Pinter, et al.
Published: (2021-08-01)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01)